CombiMatrix Introduces DNA Synthesizer for Microarrays

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Aug. 9, 2005--Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) announced today that its CombiMatrix group has launched the first CustomArray(TM) DNA Synthesizer, enabling researchers to build microarrays in their own facilities. For the first time, Pharmaceutical and Academic Core Facilities will have the ability to manufacture high quality commercial grade microarrays to their exact specifications with complete control over customization. This new system will allow researchers to fulfill their existing microarray requirements in addition to taking microarrays to new frontiers by exploring unique and novel applications.

"One of the biggest advantages of the CustomArray(TM) DNA Synthesizer, is the ability to fabricate commercial high quality arrays while having control over content and supply," said Michael Tognotti, Vice President of Sales and Marketing of CombiMatrix. "We have already shipped several machines and they are in use by customers at leading research organizations. We are very excited about this product and the large market it will serve."

“We have already shipped several machines and they are in use by customers at leading research organizations. We are very excited about this product and the large market it will serve.”

The platform consists of the DNA CustomArray Synthesizer instrument and freely programmable microarrays or CustomArrays. Initially, the instrument has been designed to fabricate CombiMatrix's CustomArray12K (12,000 unique sites). The synthesizer will initially be marketed to the pharmaceutical, biotechnology, diagnostic, academic, and government sectors.


CustomArrays are semiconductor-based arrays (approx. 1 cm2) integrated onto a standard 1" x 3" slide format. CustomArrays contain in situ synthesized oligonucleotides, prepared using CombiMatrix's patented virtual-flask technology. Sensitivity and performance metrics are available from the company's web site and at


Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 31 patent portfolios, which include over 120 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, Internet access redirection, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (NASDAQ:ACTG) and Acacia Research-CombiMatrix (NASDAQ:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.


Acacia Research Corporation
Bret L. Undem, 425-493-2293
Fax: 425-493-2010

Better Be Business Wired.

Business Wire is the leading source for press releases, photos, multimedia and regulatory filings from companies and groups throughout the world.